Variability of CA 125 serum concentrations in healthy women according to age, hormonal status and other factors;Variabilidad de las concentraciones séricas de CA 125 en mujeres sanas en función de la edad, situación hormonal y otras condiciones

Clinica e Investigacion en Ginecologia y Obstetricia

Volumn 33, Issue 4, 2006, Pages 122-129

  Barcelo B ^a   Barcelo A ^a   Riesco, M ^a   Perez G ^a   Castanyer, B ^a   Vila, M ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; HUMAN; MENOPAUSE; MENSTRUAL CYCLE; NORMAL HUMAN; PARITY; SMOKING;

EID: 33746329292     PISSN: 0210573X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-573X(06)74100-4     Document Type: Article

References (34)

1. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331-7.
2. Dilek I, Ayakta H, Demir C, Meral C, Ozturk M. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol. 2005;27:51-5.
3. Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA 125 and its relation to cardiac function. Am Heart J. 1999;137:1044-9.
4. Pritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem. 1998;44:1379-80.
5. Van Nagell JR, DePriest PD. Manegement of adnexal masses in postmenopausal women. Am J Obstet Gynecol. 2005;193:30-5.
6. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-7.
7. Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P. Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clin Chem. 1998;44:1417-22.
8. Koper NP, Thomas CMG, Massuger LFAG, Van der Mooren MJ, Kiemeney LALM, Verbeek ALM. Serum CA 125 concentrations in women of different ages, hormonal statuses, or clinical conditions. Int J Gynecol Cancer. 1997;7:405-11.
9. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2001;10:489-93.
10. Westgard JO. Internal quality control: planning and implementation strategies. Ann Clin Biochem. 2003;40:593-611.
11. Van Ingen HE, Chan DW, Hubl W, Miyachi H, Molina R, Pitzel L, et al. Analytical and clinical evaluation of an electrochemiluminiscence immunoassay for the determination of CA 125. Clin Chem. 1998;44:2530-6.
12. Bonfrer JMG, Korse CM, Verstraeten RA, van Kamp GJ, Hart GAM, Kenemans P. Clinical evaluation of the Byk LIA-mat CA-125 II assay: discussion of a reference value. Clin Chem. 1997;43:491-7.
13. Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76 Suppl:2004-10.
14. Zurawski VR, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC, et al. Prospective evaluation of serum CA 125 levels in a normal population, phase 1: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol. 1990;36:299-305.
15. Davelaar EM, Schutter EMJ, Von Mensdorff-Pouilly S, Van Kamp GJ, Verstraeten RA, Kenemans P. Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA 125 detecting assays. Ann Clin Biochem. 2003;40:663-73.
16. Suriyama T, Nishida T, Komai K, Nishimura H, Yakushyi M, Nishiymusa H. Comparison of Ca 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitorin ovarian cancer. Int J Gyn Obstet. 1996;54:2151-6.
17. Alagoz T, Buller RE, Berman M, Anderson B, Manetta A, DiSaia P. What is a normal CA125 level? Gynecol Oncol. 1994;53:93-7.
18. Vuento MH, Stenman UH, Pirhonen JP, Makinen JI, Laippala PJ, Salmi TA. Significanced of a single CA 125 assay combinated with ultrasound in the early detection of ovarian and endometrial cancer. Gynecol Oncol. 1997;64:141-6.
19. Bon GG, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, Van Kamp GJ, et al. Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles. Human Reproduction. 1999;14:566-70.
20. Bon GG, Kenemans P, Verstraeten R, Van Kamp GJ, Hilgers J. Serum tumor markers immunoassays in gynecologic oncology: Establishment of reference values. Am J Obstet Gynecol. 1996;174:107-14.
21. Im SS, Gordon AN, Buttin BM, Leath CA, Gostout BS, Shah C, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol. 2005;105:35-41.
22. ACOG Committee Opinion. The role of the generalist obstetrician- gynecologist in the early detection of ovarian cancer. Obstet Gynecol. 2002;100:1413-6.
23. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. N Engl J Med. 2003;348:1625-38.
24. Erbagci AB, Yilmaz N, Kutlar I. Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women. Dis Markers. 1999;15:259-67.
25. Green PJ, Ballas SK, Westkacper P, Schwartz HG, Klug TL, Zurawski VR. CA 19-9 and CA125 levels in the sera of normal blood donors in relation to smoking history. J Natl Cancer Inst (Bethesda). 1986;77:337-41.
26. Haga Y, Sakamoto K, Egami H, Yoshimura R, Akagi M. Evaluation of serum CA125 values in healthy individuals and pregnant women. Am J Med Sci. 1986;292:25-9.
27. Mastropaolo W, Fernández Z, Miller EL. Pronounced increases in the concentration of an ovarian tumor marker, CA125, in serum of a healthy subject during menstruation. Clin Chem. 1986;32:2110-1.
28. Hornstein MD, Thomas PP, Gleason RE, Barbieri RL. Menstrual cyclicity of CA-125 in patients with endometriosis. Fertil Steril. 1992;58:279-83.
29. Pittaway DE, Payes JA. Serum CA 125 antigen concentrations increases during menses. Am J Obstet Gynecol. 1987;156:75-6.
30. Hompes P, Koninckx P, Kennedy S, et al. Serum CA 125 concentrations during midfollicular phase, a clinically useful and reproducible marker in diagnosis of advanced endometriosis. Clin Chem. 1996;42:1871-4.
31. O'Shaughnessy A, Check JH, Nowroozi K, Lurie D. CA 125 levels measured in different phases of the menstrual cycle in screening for endometriosis. Obstet Gynecol. 1993;81:99-103.
32. Browning MCK, McFarlane NP. Objetive interpretation of results for tumor markers. J Nucl Med Allied Sci. 1990;34 Suppl 3:89-91.
33. Tuxen MK, Soletormos G, Petersen PH, Schioler V, Dombernowsky P. Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol. 1999;74:12-22.
34. Tuxen MK, Soletormos G, Rustin GJ, Nelstrop AE, Dombernowsky P. Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer. Scand J Clin Lab Invest. 2000;60:713-21.